Drug intelligence / Profile preview

geranyloxy-ifosfamide

Development stage: Preclinical
Lead developer: FindImmune
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

F1902, also known as geranyloxy-ifosfamide (G-IFO), is a small molecule immunomodulator developed by FindImmune. A derivative of the classical alkylating agent ifosfamide, F1902 is engineered to enhance the efficacy of anti-tumor immunotherapies, specifically when used in combination with immune checkpoint inhibitors. The compound aims to overcome tumor resistance and improve the recognition of cancer cells by the immune system. It is currently in the preclinical stage of development for oncology indications, with research focused on its ability to program macrophages and improve drug delivery within the tumor microenvironment.

Other names: geranyloxy-ifosfamide

Targets

DNA

Beyond the preview

Go deeper on geranyloxy-ifosfamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on geranyloxy-ifosfamide.

Explore the full profile